

UNCLASSIFIED

AD NUMBER
ADB264903
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; May 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, 21 Feb 2003

THIS PAGE IS UNCLASSIFIED

AD _____

Award Number: DAMD17-99-1-9281

TITLE: Estrogen-Mediated Breast Carcinogenesis: The Role of
Sulfation Pharmacogenetics

PRINCIPAL INVESTIGATOR: Araba Adjei, Ph.D.

CONTRACTING ORGANIZATION: Mayo Foundation
Rochester, Minnesota 55905

REPORT DATE: May 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, May 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010406 136

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9281

Organization: Mayo Foundation

Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Kath Mm 8/28/00

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE May 2000	3. REPORT TYPE AND DATES COVERED Annual (1 May 99 - 30 Apr 00)	
4. TITLE AND SUBTITLE Estrogen-Mediated Breast Carcinogenesis: The Role of Sulfation Pharmacogenetics			5. FUNDING NUMBERS DAMD17-99-1-9281	
6. AUTHOR(S) Araba Adjei, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mayo Foundation Rochester, Minnesota 55905 E-MAIL: adjei.araba@mayo.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, May 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The carcinogenic effects of estrogen as a result of receptor -mediated mechanisms are well established. However, a growing body of evidence suggests that estrogens may also be direct genotoxins. Specifically, the catecholestrogens (CEs), 2- hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-OHE2), 4- hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2) are estrogen metabolites that can be metabolically activated to semiquinones and quinones and form stable and depurinating DNA adducts. The depurinating DNA adducts are formed from 4-OHE1 and 4-OHE2 and they result in mutations that lead to genotoxicity and therefore breast carcinogenesis. Prevention of the genotoxic effects of these estrogen metabolites can be achieved in part through the sulfate-conjugation of the CEs, catalyzed by Sulfotransferase (SULT) enzymes. Many of the human cytosolic SULTs are genetically polymorphic, thus, inherited differences in the activities of these enzymes may contribute to the pathophysiology of breast cancer. As such, we determined the activity of 13 recombinant human SULTs with both 4-OHE1 and 4-OHE2, and also with the other CEs, 2-OHE1 and 2-OHE2 and the parent estrogens, estrone (E1) and 17- β estradiol (E2). All but one of the SULTs studied catalyzed these reactions to varying degrees. SULT 1E1 had the highest affinity for the CEs, with apparent Km values of 0.31 and 0.18 μ M for 4-OHE1 and 4-OHE2 respectively. These results suggest that any individual variation in the sulfate conjugation of CEs catalyzed by SULTs may represent a risk factor for breast cancer.				
14. SUBJECT TERMS Breast Cancer, Pharmacogenetics, Sulfation, Sulfotransferases, Catecholestrogens				15. NUMBER OF PAGES 18
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

___ Where copyrighted material is quoted, permission has been obtained to use such material.

___ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

___ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

ACG S fei 5/25/00
PI - Signature Date

TABLE OF CONTENTS

FRONT COVER	
STANDARD FORM (SF) 298, REPORT DOCUMENTATION PAGE	2
FOREWORD.....	3
TABLE OF CONTENTS.....	4
INTRODUCTION.....	5
BODY	5
KEY RESEARCH ACCOMPLISHMENTS	7
REPORTABLE OUTCOMES.....	7
CONCLUSIONS	7
REFERENCES.....	8
APPENDICES	11

INTRODUCTION

The carcinogenic effects of estrogen as a result of receptor-mediated mechanisms are well established. However, a growing body of evidence suggests that estrogens may also be direct genotoxins. Specifically, the catecholestrogens (CEs), 2-hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-OHE2), 4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2) are estrogen metabolites that can be metabolically activated to semiquinones and quinones and form stable and depurinating DNA adducts. The depurinating DNA adducts are formed from 4-OHE1 and 4-OHE2 and they result in mutations that lead to genotoxicity and therefore breast carcinogenesis. Prevention of the genotoxic effects of these estrogen metabolites can be achieved in part through the sulfate-conjugation of the CEs, catalyzed by sulfotransferase (SULT) enzymes. Many of the SULTs are genetically polymorphic, thus, inherited differences in the activities of these enzymes would imply variations in enzyme activities towards the inactivation of the CEs. This would therefore lead to variations in the formation of the genotoxins that result in carcinogens-- ultimately contributing to the risk of breast cancer.

BODY

Task 1 was to determine which of the known human SULT isoforms and allozymes are capable of catalyzing the sulfate-conjugation of the catecholestrogens 2-OHE1, 2-OHE2, 4-OHE1 and 4-OHE2. Recombinant SULT proteins developed in our laboratory was used for the Substrate Kinetic studies. A latter addition to this Task was the inclusion of the parent estrogens, Estrone (E1) and Estradiol (E2), whose metabolites are the CEs. 1-6 months.

This Task has been completed. The modified method of Foldes and Meek for assaying SULTs was used for the substrate kinetic studies.

Figures 1 and 2 and Tables 1, 2, 3 and 4 in the Appendix are the results obtained from this study. **THESE RESULTS ARE IN A MANUSCRIPT BEING PREPARED FOR PUBLICATION.**

An **ABSTRACT** pertaining to this work can also be found in the appendix. This Abstract was chosen for an oral presentation at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) annual meeting held in California, in March 2000, and it received the 2000 Presidential Trainee Award for the Society.

Task 2 was to use immunohistochemical techniques to localize the SULT isoform(s), which show relatively high affinities for the CEs, in normal and neoplastic breast tissues. 6-12 months.

Immunohistochemical studies were performed initially using SULT1E1 antiserum and 20 samples of paraffin-embedded breast cancer tissue sections, and 10 samples of frozen sections of normal breast tissue. Results showed that there was non-specific background staining, and therefore it was difficult to classify the staining as positive or negative. Because of the ambiguity of the results, a decision was made to purify the antiserum.

This polyclonal antiserum had not been originally purified, therefore a purification procedure using Protein A Sepharose CL-4B from Pharmacia Biotech was used to isolate and purify the IgG, which was then lyophilized.

To verify that the purified antibody was indeed that for SULT1E1, a Western blot was performed with recombinant SULT1E1. After ECL detection, results showed a single distinct band around 35KD, the known size of SULT1E1. This purified and lyophilized SULT1E1 antibody will be reconstituted to a higher concentration and used to repeat the immunohistochemical assays. If required, further affinity purification with recombinant SULT1E1 protein will be performed.

Task 3 was to test the hypothesis that there are functionally significant genetic polymorphisms within the specific SULT gene(s) identified and to develop allele-specific restriction digestion assays for these sequences to enable rapid genotyping. 7-24 months.

The Task 3 project as described in the Statement of work has not been initiated, but some work has been done to initiate the Task. Task 3 is the follow up of Task 2, where the SULT with highest affinity for the catecholestrogen, (SULT1E1) is to be used for immunohistochemical studies for possible localization. As explained in Task 2, there was such ambiguity in the results that I have recently purified the SULT1E1 antibody, which will be used to repeat the immunohistochemistry studies.

As a step towards accomplishing Task 3 and also as a step towards identifying the polymorphisms that may be present in SULT1E1, I have started the resequencing of this SULT. Resequencing is defined as seeking the common variant alleles of a gene(s), which are functionally important. Resequencing is used to describe the process of PCR amplification of many DNA samples (about 100) for all the exons and sections of introns immediately 5' and 3' to the exons in the gene(s) of interest, followed by sequencing analyses and calculation for allele-frequencies. At this time, instead of isolating DNA from normal breast tissues samples, we have available, DNA (M90PDR) from the Coriell Cell Repositories – i.e. the DNA Polymorphism Discovery Resource. This DNA resource comprises DNA from different ethnic backgrounds (25% each, African Americans, Native American, Hispanics and Caucasians). These samples have been stripped of all identifiers. A total of 90 DNA samples is provided in M90PDR. This is the DNA source that has been recommended for use in the recently funded UO1 grant for the Pharmacogenetic Research Network and Knowledge Base, of which Dr. Weinshilboum, a co-investigator on this DOD Grant and in whose laboratory I reside, is a recipient. SULT 1E1 has eight (8) exons and these have been amplified using intron-based primers located approximately 100 to 150bp 5' and 3' of each of the exons. The exons were amplified with M13-tagged sequences for subsequent dye-primer sequencing--- a sequencing method that can identify unequivocally the heterozygous nature of amplicons. In addition, presence or absence of any insertion or deletion events can be identified. Analysis of the amplified sequences is being performed with a Computer program called Polyphred. This program helps to accurately identify heterozygous sites in sequences produced with fluorescence-based chemistries. The program compares sequence traces and searches for homozygotes and heterozygotes by the detection of a significant drop in fluorescence peak height at a variant site when sequence traces obtained from both homozygote and heterozygote individuals are compared.

Information obtained from all 90 samples is rapid so that in this particular case “relative allele frequencies” for the single nucleotide polymorphisms (SNPs) identified can be calculated. In addition, those SNPs, which will change encoded amino acids, can be tested for activity and functional significance. Thus knowing the genotype and the activity it elicits will lead to genotype – phenotype correlations. Overall, the results from this resequencing project will complement Specific Aim’s 3 and 4 of this grant, so that after identifying the SNPs and determining which have functional importance, allele-specific digestion assays can be developed rapidly for use in these two aims-3 and 4.

KEY RESEARCH ACCOMPLISHMENTS

Task 1 was completed.

An oral presentation of the results was given at the 101st Annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), in March 2000, at Los Angeles, CA.

The Abstract received the 2000 Presidential Trainee Award for ASCPT.

REPORTABLE OUTCOMES

A manuscript entitled CATECHOL ESTROGEN METABOLISM: POSSIBLE ROLE FOR SULFATION AND CARCINOGENESIS is in preparation.

CONCLUSIONS

As a step towards identifying whether sulfate –conjugation catalyzed by SULTs may represent an independent risk factor for the development of breast cancer, we have determined that the catecholestrogens are substrates for most of the SULTs. We also determined that SULT 1E1 had the highest affinity for 4-OHE2, the CE responsible for forming the genotoxins that form carcinogens.

REFERENCES

- Bolton, J.L. and Shen, L. p-Quinone methides are the major decomposition products of catecholesterogen o-quinones. *Carcinogenesis* **17**:925-929 (1996).
- Campbell, N.R.C., Van Loon, J.A. and Weinshilboum, R.M. Human liver phenol sulfotransferase: assay conditions, biochemical properties and partial purification of isozymes of the thermostable form. *Biochem. Pharmacol.* **36**:1435-1446, 1987.
- Castagnetta, L.A., Granata, O.M., Arcuri, F.P., Polito, L.M., Rosati, F. and Cartoni, G.P. Gas chromatography/mass spectrometry of catechol estrogens. *Steroids* **57**:437-43 (1992).
- Castles, C.G. and Fuqna, S.A.W. Alterations within the estrogen receptor in breast cancer. In: Hormone-Dependent Cancer. (J.R. Pasqualini and B.S. Katzenellebogen, eds.) Marcel Dekker, Inc., New York, pp. 81-105 (1996).
- Cavalieri, E.L., Stack, D.E., Devanesan, P.D., Todorovic, R., Dwivedy, I., Higginbotham, S., Johannson, S.L., Patil, K.D., Gross, M.L., Gooden, J.K., Ramanathan, R., Cerny, R.L. and Rogan, E.G. Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. *Proc. Natl. Acad. Sci. USA* **94**:10937-10942 (1997).
- Cleland, W.W. Computer programmes for processing enzyme kinetic data. *Nature (Lond.)* **198**:463-465 (1963).
- Coughtrie, M.H.W., Sharp, S., Maxwell, K. and Innes, N.P. Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases. *Chem-Biol. Interac.* **109**:3-27 (1998).
- Foldes, A. and Meek, J.L. Rat brain phenolsulfotransferase - partial purification and some properties. *Biochim. Biophys. Acta.* **327**:365-374 (1973).
- Her, C., Wood, T.C., Eichler, E.E., Mohrenweiser, H.W., Ramagli, L.S., Siciliano, M.J. and Weinshilboum, R.M. Human hydroxysteroid sulfotransferase SULT2B1: two enzymes encoded by a single chromosome 19 gene. *Genomics* **53**:284-295 (1998).
- Hernández, J.S., Watson, R.W.G., Wood, T.C. and Weinshilboum, R.M. Sulfation of estrone and 17 β -estradiol in human liver: catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase. *Drug Metab. Dispos.* **20**:413-422 (1992).
- Hobkirk, R. Steroid sulfation. *Trends Endocrinol. Metab.* **4**:69-74 (1993).

- Lavigne, J.A., Helzlsouer, K.J., Huang, H-Y., Strickland, P.T., Bell, D.A., Selmin, O., Watson, M.A., Hoffman, S., Comstock, G.W. and Yager, J.D. An association between the allele coding for a low activity variant of catechol O-methyltransferase and the risk for breast cancer. *Cancer Res.* **57**:5493-5497 (1997).
- Liehr, J.G. Mechanism of metabolic activation and inactivation of catecholestrogens: a basis of genotoxicity. *Polycyclic Aromatic Compounds* **6**:229-39 (1994).
- Martucci, C.P. and Fishman, J. P450 enzymes of estrogen metabolism. *Pharmacol. Ther.* **57**:237-257 (1993).
- Meisheri, K.D., Cipkus, L.A. and Taylor, C.J. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K⁺ permeability. *J. Pharmacol. Exp. Ther.* **245**:751-760 (1988).
- Nandi, S., Guzman, R.C. and Yang, J. Hormones and mammary carcinogenesis in mice, rats and humans: a unifying hypothesis. *Proc Natl Acad Sci* **92**:3650-7 (1995).
- Pasqualini, J.R. and Kincl, F. Hormones and the Fetus. Vol. 1. pp. 173-334. Oxford: Pergamon, (1985).
- Preston-Martin, S., Pike, M.C., Ross, R.K., Jones, P.A. and Henderson, B.E. Cell proliferation and chemical carcinogenesis. An International Symposium. Research Triangle Park, NC. (1992).
- Raftogianis, R.B., Wood, T.C., Otterness, D.M., Van Loon, J.A. and Weinshilboum, R.M. Phenol sulfotransferase pharmacogenetics in humans: association of common *SULT1A1* alleles with TS PST phenotype. *Biochem. Biophys. Res. Commun.* **239**:298-304 (1997).
- Raftogianis, R.B., Wood, T.C. and Weinshilboum, R.M.: Human phenol sulfotransferases *SULT1A2* and *SULT1A1*: genetic polymorphisms, allozyme properties and human liver genotype-phenotype correlations. *Biochem. Pharmacol.* **58**:605-610 (1999).
- Suiko, M., Sakakibara, Y. and Liu, M-C. Sulfation of Environmental Estrogen-like Chemicals by Human Cytosolic Sulfotransferases. *Biochem and Biophys Res Com* **267**: 80-84 (2000).
- Thompson, P.A., Shields, P.G., Freudenheim, J.L., Stone, A., Vena, J.E., Marshall, J.R., Graham, S., Laughlin, R., Nemoto, T., Kadlubar, F.F. and Ambrosone, C.B. Genetic polymorphisms in catechol O-methyltransferase, menopausal status, and breast cancer risk. *Cancer Res.* **58**:2107-2110 (1998).

Watabe, T., Ishizuka, T., Isobe, M. and Ozawa, N. A 7-hydroxymethylsulfate ester as an active metabolite of 7,12-dimethylbenz[a]anthracene. *Science* **215**:403-405 (1982).

Weinshilboum, R.M. and Otterness, D.M.: Sulfotransferase enzymes. IN: Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity, chapter 22, edited by F.C. Kauffman, "Handbook of Experimental Pharmacology" series, volume 112, pp. 45-78, Springer-Verlag, Berlin Heidelberg, (1994).

Wilkinson, G.N. Statistical estimations in enzyme kinetics. *Biochem. J.* **80**:324-332 (1961).

Yager, J.D. and Liehr, J.G. Molecular mechanisms of estrogen carcinogenesis. *Ann. Rev. Pharmacol. Toxicol.* **36**:203-232 (1996).

Yoshinari, K., Nagata, K., Shimada, M. and Yamazoe, Y. Molecular characterization of ST1C1 related human sulfotransferase. *Carcinogenesis* **19**(5):951-3 (1998).

Zhu, B.T., Bui, Q.D., Weisz, J. and Liehr, J.G. Conversion of estrone to 2- and 4-hydroxyestrone by hamster kidney and liver microsomes: implications for the mechanism of estrogen-induced carcinogenesis. *Endocrinology* **135**:1772-9 (1994).

Zhang, H., Varmalova, O., Vargas, F.M., Falany, C.N. and Leyh, T. Sulfuryl Transfer: The Catalytic Mechanism of Human Estrogen Sulfotransferase. *J. Biol. Chem.* **273**(18): 10888-92 (1998).

APPENDICES

Appendix I :

SULFATE CONJUGATION AND ESTROGEN-MEDIATED CARCINOGENESIS.

A.A. Adjei*, T.C.Wood*, P.C. Roche* and R.M. Weinshilboum.

Mayo Fdn., Rochester, MN.

The carcinogenic effects of estrogens as a result of receptor-mediated mechanisms are well established, but a growing body of evidence indicates that estrogens may also be direct genotoxins. Specifically, catecholestrogens (CEs) such as 4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2) are estrogen metabolites that can be metabolically activated to quinones which can form depurinating DNA adducts. Prevention of the genotoxic effects of these estrogen metabolites can be achieved, in part, by the sulfate conjugation of CEs catalyzed by sulfotransferase (SULT) enzymes. Many human SULTs are genetically polymorphic, so inherited differences in the activities of these enzymes might contribute to the pathophysiology of breast cancer. Therefore, we have determined the activity of 13 recombinant human SULTs with both 4-OHE1 and 4-OHE2 as substrates. All but one of the enzymes studied could catalyze these reactions to varying degrees, but SULT1E1 had the highest affinity for the CEs, with apparent K_m values of 0.31 μM for 4-OHE1 and 0.18 μM for 4-OHE2. We have also localized SULT1E1 to benign human breast tissue by immunohistochemical methods. These results indicate that individual variation in the sulfate conjugation of CEs catalyzed by SULTs may represent a risk factor for breast and other cancers.

Supported with Grant DAMD17-99-1-9281

Appendix II : See attached Figures and Tables on pages 12-17.

N.B.

ALL FIGURES AND TABLES IN APPENDIX II ARE PROPRIETARY DATA.

Figure 1

Estrogen-Induced Carcinogenesis Possible Role for Sulfation




Figure 2

Human SULT1E1 Substrate Kinetics




Table 1

Estrogen-Induced Carcinogenesis K_m Values for 2-OH E1 (E2)

SULT Isoform	Apparent K _m Values ($\mu\text{M} \pm \text{S.E.}$)	
	2-OH E1	2-OH E2
1A1*1	5.3 ± 1.3	2.5 ± 0.2
1A1*2	3.6 ± 2.8	11.6 ± 0.5
1A1*3	3.6 ± 0.4	17.3 ± 2.0
1A2*1	19.6 ± 2.4	10.7 ± 1.6
1A2*2	31.5 ± 3.2	484.5 ± 75.1
1A2*3	8.9 ± 1.2	40.8 ± 2.6
1A3	188.4 ± 4.0	81.8 ± 6.9
1C1	ND	ND
1E1	0.27 ± 0.08	0.22 ± 0.03
2A1	12.7 ± 1.3	2.4 ± 0.1
2B1a	6.7 ± 1.5	3.3 ± 0.4
2B1b	3.3 ± 0.5	2.5 ± 0.1

ND = no detectable activity

Table 2

Estrogen-Induced Carcinogenesis K_m Values for 4-OH E1 (E2)

SULT Isoform	Apparent K_m Values ($\mu\text{M} \pm \text{S.E.}$)	
	4-OH E1	4-OH E2
1A1*1	53.8 ± 2.1	44.0 ± 5.2
1A1*2	53.3 ± 9.3	23.4 ± 3.7
1A1*3	40.4 ± 4.4	6.3 ± 0.1
1A2*1	17.1 ± 2.0	27.9 ± 0.7
1A2*2	65.1 ± 9.4	42.4 ± 2.7
1A2*3	5.1 ± 0.8	7.6 ± 2.0
1A3	32.4 ± 3.7	475.8 ± 93.8
1C1	ND	ND
1E1	0.31 ± 0.13	0.18 ± 0.06
2A1	20.4 ± 1.0	41.5 ± 19.5
2B1a	20.7 ± 1.8	45.2 ± 13.0
2B1b	13.6 ± 0.4	17.5 ± 1.0

ND = no detectable activity

Table 3

**Estrogen-Induced Carcinogenesis
Km Values for E1 and E2**

SULT Isoform	Apparent Km Values $\mu\text{M} \pm \text{S.E.}$	
	E1 (ESTRONE)	E2 (ESTRADIOL)
1A1*1	ND	31.3 ± 6.2
1A1*2	ND	84.6 ± 24.3
1A1*3	ND	21.1 ± 2.9
1A2*1	ND	28.6 ± 3.8
1A2*2	ND	145.4 ± 21.3
1A2*3	ND	18.3 ± 2.2
1A3	ND	ND
1C1	ND	ND
1E1	0.11 ± 0.1	0.097 ± 0.06
2A1	11.2 ± 0.9	12.4 ± 0.9
2B1a	ND	84.3 ± 7.6
2B1b	ND	60.9 ± 10.0

ND - Little or no detectable activity .

Table 4

SULT1E1 Substrate Kinetics

<u>Substrate</u>	<u>K_m</u> (μ M)	<u>V_{max}</u> (Units/mg protein)	<u>V_{max}/K_m</u>
E2	0.097	6.88	70.9
E1	0.11	4.13	37.5
4-OH E2	0.18	6.04	33.6
2-OH E2	0.22	4.77	21.7
4-OH E1	0.31	2.35	7.6
2-OH E1	0.27	1.61	6.0



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

21 Feb 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218


SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl


PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

ADB263458	ADB282838
ADB282174	ADB233092
ADB270704	ADB263929
ADB282196	ADB282182
ADB264903	ADB257136
ADB268484	ADB282227
ADB282253	ADB282177
ADB282115	ADB263548
ADB263413	ADB246535
ADB269109	ADB282826
ADB282106	ADB282127
ADB262514	ADB271165
ADB282264	ADB282112
ADB256789	ADB255775
ADB251569	ADB265599
ADB258878	ADB282098
ADB282275	ADB232738
ADB270822	ADB243196
ADB282207	ADB257445
ADB257105	ADB267547
ADB281673	ADB277556
ADB254429	ADB239320
ADB282110	ADB253648
ADB262549	ADB282171
ADB268358	ADB233883
ADB257359	ADB257696
ADB265810	ADB232089
ADB282111	ADB240398
ADB273020	ADB261087
ADB282185	ADB249593
ADB266340	ADB264542
ADB262490	ADB282216
ADB266385	ADB261617
ADB282181	ADB269116
ADB262451	
ADB266306	
ADB260298	
ADB269253	
ADB282119	
ADB261755	
ADB257398	
ADB267683	
ADB282231	
ADB234475	
ADB247704	
ADB258112	
ADB267627	